Table 2.
Baseline characteristics of esophageal NENs.
| Variable | Number (percentage) |
|---|---|
| Age | |
| <40 years | 5 (11.6%) |
| 40–60 years | 15 (34.9%) |
| >60 years | 23 (53.5%) |
|
| |
| Gender | |
| Male | 26 (60.5%) |
| Female | 17 (39.5%) |
|
| |
| Symptoms | |
| Dysphagia | 38 (88.3%) |
| Abdominal/retrosternal pain | 9 (22.5%) |
| Loss of weight or loss of appetite | 8 (18.6%) |
| Gastrointestinal bleed | 2 (4.6%) |
| Carcinoid syndrome | 0 |
|
| |
| Performance status | |
| 1/2 | 34 (79%) |
| 3 | 9 (21%) |
|
| |
| Esophagus tumor location | |
| Upper third (15–25 cm from incisor) | 1 (2.3%) |
| Middle third (25–30 cm from incisor) | 7 (16.3%) |
| Lower third, GE junction (30–40 cm from incisor) | 35 (81.4%) |
|
| |
| Mitotic count and Ki-67 index (WHO, [21]) | |
| G1: <2/10 HPF's; <2% | 0 |
| G2: 2–20/10 HPF's; 3–20% | 7 (16.3%) |
| G3: >20/10 HPF's; >20% | 36 (83.7%) |
|
| |
| Disease stage | |
| I | 0 |
| II | 6 (14%) |
| III | 14 (32.5%) |
| IV | 23 (53.5%) |
|
| |
| Treatment received | |
| STAGE II, III (n = 20; 46.5%) | mOS = 18.25 m (2.5–60 m) n = 13 |
| Upfront surgery (THE/TTE) +/− CT | mOS = 18.5 m (2.5–60 m) n = 2 |
| NACT plus surgery | mOs = 15.25 m |
| Received Chemo/Oct LAR only | n = 7 mOS = 12 m (6–30 m) |
| STAGE IV (n = 23; 53.5%) | mOS = 6.5 (1.5–32 m) |
| Cisplatin + etoposide | n = 21 mOS = 6.5 m (1.5–32 m) |
| Octreotide LAR | n = 2 mOS = 16 m |
|
| |
| mOS stage II (n = 6) | 43 m (18–60 m) |
|
| |
| mOS stage III (n = 14) | 12.5 m (6–30 m) |